2023-01-26 01:08:00

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in...

Logo PR Newswire
PR Newswire

"Expected to change GERD drug market landscape"

  • Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted to Colombia, Vietnam, and Saudi Arabia
  • NDA submissions in 11 countries completed in the shortest time among K-pharma new drugs... accelerating expansions into $1.61 billion market

SEOUL, South Korea, Jan. 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's Fexuclue (active ingredient: Fexuprazan) is attracting attention as a game changer in the global gastroesophageal reflux disease (GERD) treatment market as it applied for approval in 11 countries across the world within one year after approval in Korea.

The company said on the 25th that it recently submitted a new drug application (NDA) for Fexuclue, a GERD drug, in Saudi Arabia. With this application, Daewoong completed NDA applications in 11 countries around the world in one year after securing permission for Fexuclue in Korea.

According to the 2021 data of IQVIA Global MIDAS, a pharmaceutical market research firm, the cumulative anti-ulcer drug market in 11 countries where Daewoong Pharmaceutical has submitted product approvals is estimated to be worth $1.61 billion (2 trillion won). The 11 countries in which the company has thus far submitted applications for Fexuclue approval include Brazil, the Philippines, Indonesia, Thailand, Mexico, Chile, Ecuador, Peru, Colombia, Vietnam, and Saudi Arabia.

Daewoong has also completed the submission of NDA for all four Latin American countries (Colombia, Ecuador, Peru, and Chile) that signed out-license agreements in 2021, and submitted an NDA to Vietnam to further accelerate its advance into the Asian market.

Based on the recent achievement to make a partnership with 15 countries, the company plans to further accelerate its global expansion for the growth of its blockbuster new drug. First of all, it plans to apply for product approval in 30 countries across the world by 2025 and launch in 100 countries by 2030. In particular, it won product approval in the Philippines in November last year for the first time in the world, and this year it will submit an application for product approval to advance into China, which has grown into the world's largest anti-ulcer drug market beyond the United States with a market size of $3.53 billion (4.37 trillion won) as of 2021.

Fexuclue Tablet is a new drug for GERD officially launched by Daewoong Pharmaceutical in Korea in July last year and is a potassium-competitive acid blocker (P-CAB) drug. By improving the drawbacks of existing proton pump inhibitors (PPIs), it binds to the proton pump without activating gastric acid and quickly and stably inhibits the secretion of gastric acid. There are two indications it has secured so far: treatment of erosive GERD (40 mg) and improvement of gastric mucosal lesions in acute and chronic gastritis (10 mg). In particular, Fexuclue is the only P-CAB drug for gastritis indications in Korea. The compound patent expires approximately in 2036, with extension potential.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical, said, "The fact that Fexuclue completed applications for approval in the most countries in such a short period of time after approval among new drugs developed in Korea proves our cumulative know-how and ability to develop global new blockbuster drugs. Along with the sequential expansion of overseas approval and launch, we will accelerate not only the expansion of indications through the promotion of multifaceted clinical trials but also but also diversify formulation to improve the value of product."

Daewoong Pharmaceutical is conducting phase 3 clinical trials for additional indications for maintenance therapy after treatment of erosive GERD and prevention of ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs), and also commenced on clinical trials for eradicating Helicobacter pylori. In addition, it is preparing to expand its lineup through the development of orally disintegrating tablets and IV formulations (injections) for patient convenience.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-submitted-nda-for-its-global-new-drug-fexuclue-in-11-countries-only-1-year-after-approval-in-korea-301731095.html

SOURCE Daewoong Pharmaceutical Co., Ltd.

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 16:02:00
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:03:00
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...

Logo PR Newswire
HealthPress Release2023-01-25 22:40:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Pharmaceutical API Manufacturing Global Market Opportunities And Strategies To 2031" report has been added to...

Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo PR Newswire
HealthPress Release2023-01-25 20:30:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global Opportunity Analysis and...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo PR Newswire
HealthPress Release2023-01-25 02:15:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The GERD Market by Route of Administration, Type, and Geography - Forecast and Analysis 2023-2027 report has been...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 14:55:00
This legislation is expected to create more demand for GATC's drug discovery and development platform as AI and machine learning are increasingly used in...

Logo PR Newswire
HealthPress Release2023-01-25 17:30:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Insomnia Market Size, Share & Industry Trends Analysis Report by Distribution Channel, Therapy Type,...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc....

Logo PR Newswire
HealthPress Release2023-01-25 16:20:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "North America Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 06:30:00
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...

Logo PR Newswire
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Food Allergy Diagnostics & Therapeutics Market (2022-2027) by Product Type, Source, End-user, and...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (First Wave BioPharma or the Company), a clinical-stage...

Logo PR Newswire
HealthPress Release2023-01-25 23:00:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:30:00
Isranalytica 2023, the A nnual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug...

Logo GlobeNewswire
EconomyPress Release2023-01-25 15:00:00
Embolotherapy Market Size By Disease (Oncology, Peripheral Vacsular Diseases and Others), By Embolic Agents (Liquid Embolic Agent, Microspheres, Embolic...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:30:00
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

Logo PR Newswire
HealthPress Release2023-01-25 13:00:00
Features new highlights and rankings of the top 50 drug classes by percent of net spend EAGAN, Minn., Jan. 25, 2023 /PRNewswire/ -- Magellan Rx Management...